What is nine-valent HPV

The nine-valent HPV vaccine is used to prevent cervical cancer caused by human papillomavirus (HPV) infection and can prevent more than 90% of cervical cancer. The vaccine was approved for sale abroad in 2014. On April 28, 2018, the National Medical Products Administration approved the sale of the nine-valent HPV vaccine for the prevention of cervical cancer in my country. Vaccination is the primary prevention, and screening is the secondary prevention, and both are equally important. Therefore, cervical cancer screening measures cannot be relaxed just because of vaccination.

What is the nine-valent HPV vaccine?

The nine-valent HPV vaccine is a cervical cancer vaccine. Women can avoid cervical cancer after taking it.

HPV stands for human papillomavirus infection. This virus infection is closely related to cervical cancer in women. According to the risk level of viral infection to women, they are divided into high-risk and low-risk types. In addition, this virus has more than 100 subtypes, among which the high-risk type is most closely related to cervical cancer in women.

Women can avoid cervical cancer by getting the nine-valent cervical cancer vaccine. The nine-valent cervical cancer vaccine is suitable for women aged 16-26.

The nine-valent HPV vaccine has good antigenicity. After completing the three-dose vaccination program, the positive conversion rate of serum antibodies of the relevant types can reach almost 100%. One month after the vaccination program, the maximum geometric mean antigen titer reached 100 times the antigen level after natural infection. In the next two months, the value dropped to 10 times, reaching the weight loss bottleneck period. The vaccine's antigenic level can be maintained for at least 4 years. In clinical studies of the efficacy of the nine-valent HPV vaccine, the key observation endpoints were persistent infection with other HPV types, genital warts associated with relevant HPV types, cervical intraepithelial neoplasia (CIN), and genital or vaginal intraepithelial neoplasia (VIN or VaIN). Clinical studies have shown that vaccination with the nine-valent HPV vaccine can produce good protective effects, effectively reducing persistent infection with certain types of HPV and precancerous lesions of the cervix, vagina, and genitals, and the protective effectiveness can reach more than 90%. The nine-valent HPV vaccine includes HPV-6 and HPV-11 VLPs, which have a good preventive effect on genital warts.